Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
AlconXSWX:ALC -1.21%69 3-Year FCF Growth Rate is 42.70% as of Jun. 2026, which is 95% above its 10-year median of 21.90. GuruFocus rates XSWX:ALC with a GF Score™ of 69/100 and a GF Value™ of CHF72.24 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 585 Medical Devices & Instruments companies, Alcon ranks better than 75.9% on this metric.
During the past 12 months, Alcon's average Free Cash Flow per Share Growth Rate was -18.10% per year.
During the past 3 years, the average Free Cash Flow per Share Growth Rate was 42.70% per year.
During the past 5 years, the average Free Cash Flow per Share Growth Rate was 53.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
During the past 10 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Alcon was 101.60% per year. The lowest was -31.70% per year. And the median was 21.90% per year.
Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.
Alcon 3-Year FCF Growth Rate Related Terms
XSWX:ALC vs ISRG, BDX, RMD: 3-Year FCF Growth Rate Comparison
For the Medical Instruments & Supplies subindustry, Alcon's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alcon 3-Year FCF Growth Rate vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Alcon's 3-Year FCF Growth Rate distribution charts can be found below:
* The bar in red indicates where Alcon's 3-Year FCF Growth Rate falls into.
This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.
What does a 3-Year FCF Growth Rate of 42.70% mean?
Alcon (XSWX:ALC) has a 3-Year FCF Growth Rate of 42.70% as of Jun. 2026. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Alcon and its competitors. This is 95% above median its historical median of 21.90. According to the industry distribution chart, Alcon ranks #141 out of 585 companies in the Medical Devices & Instruments industry, placing it in the top 24.1%.
Is Alcon's 3-Year FCF Growth Rate too high?
Alcon's current 3-Year FCF Growth Rate of 42.70% is 95% above median its 10-year median of 21.90. The Medical Devices & Instruments industry median 3-Year FCF Growth Rate is 18.00. Alcon's value of 42.70% is 137.2% above this industry median. Based on the distribution chart, Alcon ranks #141 out of 585 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Alcon has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Alcon's 3-Year FCF Growth Rate compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Alcon ranks #141 out of 585 companies for 3-Year FCF Growth Rate. This places Alcon in the top 24% of its industry — outperforming the majority of peers. The industry median 3-Year FCF Growth Rate is 18.00. Alcon's value of 42.70% is 137.2% above this benchmark. While the company's 10-year median is 21.90 vs. the industry median of 18.00, Alcon has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year FCF Growth Rate for a Medical Devices & Instruments company?
The median 3-Year FCF Growth Rate among Medical Devices & Instruments companies is 18.00, based on 585 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year FCF Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year FCF Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Alcon's current 3-Year FCF Growth Rate of 42.70% is 137.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year FCF Growth Rate mean?
A high 3-Year FCF Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year FCF Growth Rate is the 3-year average growth rate of Free Cash Flow per Share. View historical data for Alcon and its competitors. For the Medical Devices & Instruments industry, the median 3-Year FCF Growth Rate is 18.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alcon's current 3-Year FCF Growth Rate is 42.70%, which is 95% above median its own 10-year median of 21.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alcon stock overvalued right now?
Based on GuruFocus' analysis, Alcon (XSWX:ALC) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF72.24, compared to a current price of CHF57.30 — trading 20.7% below its estimated fair value. The current 3-Year FCF Growth Rate is 42.70%, which is 95% above median its 10-year median of 21.90 and 137.2% above the Medical Devices & Instruments industry median of 18.00. Alcon's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year FCF Growth Rate calculated?
3-Year FCF Growth Rate is calculated from a company's financial statements. For Alcon (XSWX:ALC), the current 3-Year FCF Growth Rate is 42.70% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Alcon (XSWX:ALC) Overvalued in 2026?
Based on GuruFocus' analysis, Alcon stock appears to be undervalued.
The current stock price of CHF57.30 is trading 20.7% below its estimated GF Value™ of CHF72.24.
GuruFocus considers Alcon to be Modestly Undervalued.
Key valuation signals for XSWX:ALC:
3-Year FCF Growth Rate: 42.70% (95% above median its 10-year median of 21.90)
GF Value™: CHF72.24 vs. price of CHF57.30 (20.7% below fair value)
Industry Position: 137.2% above the Medical Devices & Instruments median (#141 of 585)
No single metric tells the full story. See the XSWX:ALC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls about one fourth of the US contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.
69GF Score
Get the complete analysis for XSWX:ALC
3-Year FCF Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ALC has been successfully added to your 
